Atossa Genetics (ATOS)
(Delayed Data from NSDQ)
$0.81 USD
-0.03 (-3.44%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $0.80 -0.01 (-0.62%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Atossa Genetics Inc. has a market cap of $107.69M, which represents its share price of $0.83 multiplied by its outstanding shares number of 129.17M. As a small-cap company, ATOS's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ATOS 0.81 -0.03(-3.44%)
Will ATOS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ATOS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATOS
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?
All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy
ATOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
TCMD Stock Rises 20% in Three Months: Should You Buy, Hold or Sell?
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?
Other News for ATOS
Atossa Therapeutics reports 'positive' FDA feedback regarding (Z)-endoxifen
Atossa Therapeutics (ATOS) Gains FDA Support for Breast Cancer Drug Trial
Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen ...
Ascendiant Reaffirms Their Buy Rating on Atossa Therapeutics (ATOS)
Atossa Therapeutics (ATOS): Ascendiant Capital Raises Price Target | ATOS Stock News